This quarterly sector report details industry-specific statistics compiled from hundreds of cell therapy, gene therapy, tissue engineering, and other regenerative medicine therapeutic developers worldwide, including total financings, partnerships and other deals, clinical trial information, key clinical data events, and ARM’s current strategic priorities.
Regenerative Medicine Companies
Worldwide, Including Gene and
Cell Therapies, and Tissue Engineering
Therapeutic Developers
Decrease from Q2 2018
$4.8B Raised YTD
40% decrease YoY from H1 2018
Decrease from Q2 2018
$4.3B Raised YTD
26% decrease YoY from H1 2018
Decrease from Q2 2018
$1.5B Raised YTD
64% decrease YoY from H1 2018
Decrease from Q2 2018
$67M Raised YTD
91% decrease YoY from H1 2018
1,069
Clinical trials underway
worldwide by the end of Q2 2019
358
617
94
